We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

15 hedge funds and large institutions have $12.5M invested in CERo Therapeutics in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 5 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0.03% → 0.03% (+0%)

67% less funds holding

Funds holding: 45 → 15 (-30)

80% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 5

88% less capital invested

Capital invested by funds: $101M → $12.5M (-$88.6M)

94% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 32

Holders
15
Holders Change
-30
Holders Change %
-66.67%
% of All Funds
0.24%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
5
Closed
32
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
+$1.64M
2
BFM
Boothbay Fund Management
New York
+$527K
3
MC
Meteora Capital
Florida
+$401K

Top Sellers

Rank Fund Capital Flow
1
SCM
Saba Capital Management
New York
-$12.4M
2
HSBC Holdings
HSBC Holdings
United Kingdom
-$7.51M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.68M
4
WCMNY
Westchester Capital Management (New York)
New York
-$6.27M
5
BCM
Beryl Capital Management
California
-$5.57M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIMCA
26
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
– -$2.58M -125 Closed
Millennium Management
27
Millennium Management
New York
– -$2.23M -109 Closed
NAM
28
Nexpoint Asset Management
Texas
– -$2.24M -109 Closed
SRCM
29
Sage Rock Capital Management
New York
– -$1.89M -92 Closed
FTCM
30
Fir Tree Capital Management
New York
– -$1.75M -85 Closed
DCM
31
Difesa Capital Management
New York
– -$1.29M -63 Closed
ETH
32
Exos TFP Holdings
New York
– -$1.29M -63 Closed
Barclays
33
Barclays
United Kingdom
– -$1.09M -53 Closed
TCM
34
Tenor Capital Management
New York
– -$1.03M -50 Closed
BI
35
Bulldog Investors
New Jersey
– -$931K -45 Closed
AMC
36
Atlas Merchant Capital
New York
– -$821K -40 Closed
LCM
37
Lynwood Capital Management
Ontario, Canada
– -$613K -30 Closed
CAPTRUST Financial Advisors
38
CAPTRUST Financial Advisors
North Carolina
– -$537K -26 Closed
LCM
39
Landscape Capital Management
New Jersey
– -$506K -25 Closed
SRF
40
Silver Rock Financial
California
– -$475K -23 Closed
DFCM
41
Dark Forest Capital Management
Puerto Rico
– -$328K -16 Closed
Calamos Advisors
42
Calamos Advisors
Illinois
– -$258K -13 Closed
DCM
43
Dupont Capital Management
Delaware
– -$258K -13 Closed
KPF
44
K2 Principal Fund
Ontario, Canada
– -$124K -6 Closed
DAM
45
Deltec Asset Management
New York
– -$103K -5 Closed
RCM
46
Robinson Capital Management
Michigan
– -$76.9K -4 Closed
EC
47
Elequin Capital
New York
– -$16.4K -1 Closed
UBS Group
48
UBS Group
Switzerland
– -$29.7K -1 Closed
1
2

CERO Hedge Fund Activity: Q1 2023 in Review

15 of the 6,277 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q1 2023, worth a combined $12.5M — down 88% from $101M a quarter earlier.

Sellers outnumbered buyers: 32 funds closed out of CERO and 2 opened new positions — a net loss of 30 holders — while 5 trimmed existing stakes and 1 added.

The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $1.64M. The largest seller was Saba Capital Management, exiting entirely with an estimated $12.4M sold.

  • 15 institutional investors held CERo Therapeutics (CERO) as of Q1 2023, down from 45 in Q4 2022.
  • Funds reported $12.5M of CERo Therapeutics stock for Q1 2023, down 88% quarter-over-quarter.
  • 2 funds opened new CERo Therapeutics positions in Q1 2023 and 32 closed out, a net change of -30 holders.
  • The largest CERo Therapeutics buyer in Q1 2023 was Cantor Fitzgerald, an estimated $1.64M added.
  • The largest CERo Therapeutics seller in Q1 2023 was Saba Capital Management, an estimated $12.4M sold.

Based on aggregated 13F filings for Q1 2023.